Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xenadrine EFX manufacturer settles with FTC

This article was originally published in The Tan Sheet

Executive Summary

RTC Research and Development and the company's executives, husband and wife Robert Chinery Jr. and Tracy Chinery, settle in a case brought by the Federal Trade Commission for charges of false and unsubstantiated weight-loss claims related to their supplement Xenadrine EFX. In an April 24 release. FTC says it charged the defendants in 2005, and in 2006 the U.S. District Court for the District of New Jersey barred Robert Chinery and RTC from making claims and required RTC pay $8 million in consumer redress (1"The Tan Sheet" Aug. 13, 2007, In Brief). Tracy Chinery's motion to dismiss a similar settlement was denied in July 2007 and her motion for summary judgment was denied in March 2009, FTC says. The final settlement prohibits the Manasquan, N.J.-based firm and the Chinerys from "making any claims about the health benefits, performance, efficacy, safety, or side effects of any weight-loss product, dietary supplement, food, drug, or device" unless substantiated, true and not misleading. FTC says the defendants are not required to provide additional redress

You may also be interested in...

Xenadrine EFX refunds

The Federal Trade Commission will accept refund requests through Sept. 15 from consumers who were not satisfied with the product after buying it between Feb. 1, 2002 and May 22, 2006, the agency said in an Aug. 6 release. Under a settlement announced Jan. 4, Xenadrine EFX marketers Robert Chinery Jr., Tracey Chinery and RTC Research & Development LLC were required to pay as much as $12.8 million for consumer refunds after FTC alleged the product's weight-loss claims were false and unsubstantiated. Xenadrine EFX includes green tea extract and other caffeine sources (1"The Tan Sheet" Jan. 8, 2007, p. 4)...

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.

Global Pharma Guidance Tracker – March 2020

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts